These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Is There a Role for Immunotherapy in Prostate Cancer? Rizzo A; Mollica V; Cimadamore A; Santoni M; Scarpelli M; Giunchi F; Cheng L; Lopez-Beltran A; Fiorentino M; Montironi R; Massari F Cells; 2020 Sep; 9(9):. PubMed ID: 32911806 [TBL] [Abstract][Full Text] [Related]
47. Development of PROSTVAC immunotherapy in prostate cancer. Singh P; Pal SK; Alex A; Agarwal N Future Oncol; 2015; 11(15):2137-48. PubMed ID: 26235179 [TBL] [Abstract][Full Text] [Related]
48. Immune response to sipuleucel-T in prostate cancer. Thara E; Dorff TB; Averia-Suboc M; Luther M; Reed ME; Pinski JK; Quinn DI Cancers (Basel); 2012 Apr; 4(2):420-41. PubMed ID: 24213318 [TBL] [Abstract][Full Text] [Related]
49. Sequencing systemic therapies in metastatic castration-resistant prostate cancer. Liu JJ; Zhang J Cancer Control; 2013 Jul; 20(3):181-7. PubMed ID: 23811702 [TBL] [Abstract][Full Text] [Related]
50. Immunotherapy of Prostate Cancer: Facts and Hopes. Bilusic M; Madan RA; Gulley JL Clin Cancer Res; 2017 Nov; 23(22):6764-6770. PubMed ID: 28663235 [TBL] [Abstract][Full Text] [Related]
52. Immunotherapeutics in development for prostate cancer. Harzstark AL; Small EJ Oncologist; 2009 Apr; 14(4):391-8. PubMed ID: 19342474 [TBL] [Abstract][Full Text] [Related]
53. A comprehensive review of immunotherapies in prostate cancer. Maia MC; Hansen AR Crit Rev Oncol Hematol; 2017 May; 113():292-303. PubMed ID: 28427519 [TBL] [Abstract][Full Text] [Related]
54. Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment. Gulley JL; Madan RA; Pachynski R; Mulders P; Sheikh NA; Trager J; Drake CG J Natl Cancer Inst; 2017 Apr; 109(4):. PubMed ID: 28376158 [TBL] [Abstract][Full Text] [Related]
55. [Immunotherapy for metastatic prostate cancer: do we really need this?]. Heidenreich A Urologe A; 2012 Jan; 51(1):32-8. PubMed ID: 22258374 [TBL] [Abstract][Full Text] [Related]
56. Emerging role of immunotherapy in the management of prostate cancer. Slovin SF Oncology (Williston Park); 2007 Mar; 21(3):326-33; discussion 334, 338, 346-8. PubMed ID: 17447437 [TBL] [Abstract][Full Text] [Related]
57. From bench to bedside: immunotherapy for prostate cancer. Tse BW; Jovanovic L; Nelson CC; de Souza P; Power CA; Russell PJ Biomed Res Int; 2014; 2014():981434. PubMed ID: 25276838 [TBL] [Abstract][Full Text] [Related]
58. Immunotherapy in the treatment of advanced prostate cancer. Djavan B; Nelson K; Kazzazi A; Bruhn A; Sadri H; Gomez-Pinillos A; Ferrari AC Can J Urol; 2011 Oct; 18(5):5865-74. PubMed ID: 22018147 [TBL] [Abstract][Full Text] [Related]
59. Androgen deprivation and immunotherapy for the treatment of prostate cancer. Gamat M; McNeel DG Endocr Relat Cancer; 2017 Dec; 24(12):T297-T310. PubMed ID: 28814451 [TBL] [Abstract][Full Text] [Related]
60. Immunotherapy for prostate cancer: recent developments and future challenges. Schweizer MT; Drake CG Cancer Metastasis Rev; 2014 Sep; 33(2-3):641-55. PubMed ID: 24477411 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]